Subscribe free

Cytoreductive Surgery & Peritoneum ·

Prophylactic Hyperthermic Intraperitoneal Chemotherapy Improves Prognosis in CT4N0-1M0 Colorectal Cancer

A propensity score matching study analyzed 220 colorectal cancer patients undergoing treatment in China. Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) was associated with improved 3-year disease-free survival (DFS) compared to no HIPEC (HR 0.43). However, this benefit was not observed in patients with CT4N2M0 cancer. Laparoscopic surgery followed by HIPEC did not increase the risk of peritoneal metastasis. The study suggests that HIPEC may be an effective and safe curative treatment for selected patients with restricted peritoneal metastasis from colorectal cancer.

Journal Article by Zheng Y, Zhang J (…) Sun L et 11 al. in Eur J Surg Oncol

© 2024 Published by Elsevier Ltd.

read the whole article in Eur J Surg Oncol

open it in PubMed

Summaries are written to help you decide what to read. They do not replace the full paper.

Free · 5 minutes a day

Get every new paper in Cytoreductive Surgery & Peritoneum.

Plus the Daily Selection: the five most relevant papers of the day, each cut to its key points.

Specialty newsletters: every new paper in your field, as a list of titles linked to the source. Daily Selection: the five that matter, cut to their key points.

FreeNo spamOne-click unsubscribe

More in Cytoreductive Surgery & Peritoneum

The latest stitches

Ann Surg Oncol28 Aug 2026

Prophylactic HIPEC Improves Survival in Advanced Colorectal Cancer

Prophylactic hyperthermic intraperitoneal chemotherapy (HIPEC) significantly enhances peritoneal metastasis-free survival and disease-free survival in patients with locally advanced colorectal cancer, though overall survival rates and complication rates remain unchanged.

All papers in Cytoreductive Surgery & Peritoneum →